secwatch.observer — SEC 8-K summary
======================================

Issuer:     CERUS CORP (CERS)
CIK:        0001020214
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001193125-22-276881
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cerus Q3 revenue up 10% to $46.3M; narrows FY product revenue guidance to $160-162M
--------------------------------------------------------------------------------

- Net loss improved to $8.5M ($0.05/sh) from $12.4M ($0.07/sh) in Q3 2021.
- Product gross margin expanded to 55.4% from 51.3% YoY; adjusted EBITDA loss narrowed to $2.7M.
- Cash and investments at $103.8M; net cash used in ops $2.1M vs $6.6M prior year.
- Guidance narrowed to $160-162M product revenue from $160-165M, citing FX headwinds.
- Awarded $9.1M DoD contract for LyoCryo; Health Canada approved 7-day platelet shelf life.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1020214/000119312522276881/0001193125-22-276881-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1020214/000119312522276881/d306498d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-276881

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer